Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $13.14

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been given an average recommendation of “Hold” by the twelve ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $13.1429.

JSPR has been the subject of a number of research reports. Royal Bank Of Canada set a $3.00 target price on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday. UBS Group started coverage on shares of Jasper Therapeutics in a research note on Monday, March 23rd. They issued a “neutral” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Tuesday, April 21st. Finally, TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC acquired a new stake in shares of Jasper Therapeutics in the 1st quarter valued at $46,000. Engineers Gate Manager LP acquired a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at $78,000. Panagora Asset Management Inc. acquired a new stake in shares of Jasper Therapeutics in the 4th quarter valued at $35,000. Voleon Capital Management LP acquired a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at $50,000. Finally, XTX Topco Ltd acquired a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at $152,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Stock Down 5.1%

Shares of NASDAQ:JSPR opened at $0.81 on Friday. The firm has a fifty day moving average of $0.99 and a two-hundred day moving average of $1.41. The firm has a market capitalization of $22.58 million, a P/E ratio of -0.25 and a beta of 3.07. Jasper Therapeutics has a 12-month low of $0.62 and a 12-month high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. Equities research analysts expect that Jasper Therapeutics will post -2.09 earnings per share for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.